So, the shares are expected to perform in line with the market in the near future. Dicerna Pharmaceuticals, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $40.45 million for the quarter ended June … While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. View the latest DRNA financial statements, income statements and financial ratios. Press Release Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.Ahead of this earnings release, the estimate revisions trend for Dicerna Pharmaceuticals was mixed. We invite and inspire collaboration among employees, patients, physicians and industry partners throughout the process of drug discovery, development and commercialization.We use RNA interference, or RNAi, to create medicines that silence the genes that cause disease. Revenue of $40.45M (+612.1% Y/Y) misses by $23.8M. The current consensus EPS estimate is $0.33 on $60.11 million in revenues for the coming quarter and $1.23 on $266.66 million in revenues for the current fiscal year.Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well.
The company has not been able to beat consensus revenue estimates over the last four quarters.The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.Dicerna Pharmaceuticals shares have lost about 0.5% since the beginning of the year versus the S&P 500's decline of -11.8%.While Dicerna Pharmaceuticals has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.08 per share when it actually produced a loss of $0.58, delivering a surprise of -625%.Over the last four quarters, the company has not been able to surpass consensus EPS estimates.Dicerna Pharmaceuticals, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $34.03 million for the quarter ended March 2020, missing the Zacks Consensus Estimate by 42.92%. Dicerna Pharmaceuticals (DRNA) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of $0.28. This compares to year-ago revenues of $3.11 million. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Dicerna Pharmaceuticals Inc. annual stock financials by MarketWatch. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 5% of the 250 plus Zacks industries. Dicerna Pharmaceuticals, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $34.03 million for the quarter … Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.How Does Concert Pharmaceuticals' (NASDAQ:CNCE) CEO Salary Compare to Peers?Landec Corp (LNDC) Q4 2020 Earnings Call TranscriptSunesis Pharmaceuticals (SNSS) Reports Q2 Loss, Misses Revenue EstimatesAurinia Pharmaceuticals (AUPH) Reports Q2 Loss, Lags Revenue EstimatesGundlach, who called Trump's 2016 election, predicts he'll win againWhy Nautilus’ blowout quarter could be good news for PelotonThe big 'surprise' that could send stocks higher: Morning BriefWhy this NYC restaurant is closing its doors and relocating to DenverMicrosoft’s Surface Duo dual-screen smartphone coming Sept. 10 for $1,399Stock market news live updates: Stock futures point to a higher open; Moderna, Tesla shares extend gains Our goal is to understand and ease the unique disease-related burdens of patients and their caregivers as we create new medicines with the potential to restore their health.We’re a company that breaks down the barriers that impede our science or your ambitions. We currently have three drug candidates in clinical trials:We believe all patients deserve safe and effective medicines that can improve the quality and duration of their lives. Dicerna Pharmaceuticals, Inc., is a biopharmaceutical company using ribonucleic acid interference (RNAi) to develop medicines that silence genes that cause disease. Dicerna Pharmaceuticals (NASDAQ:DRNA): Q2 GAAP EPS of -$0.43 misses by $0.53. Our goal is to provide life-changing therapies to people living with rare diseases and common diseases that have a genetic component. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. This compares to loss of $0.38 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -210.71%. Find the latest Revenue & EPS data for Dicerna Pharmaceuticals, Inc. Common Stock (DRNA) at Nasdaq.com.